Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
Launched by SHIN POONG PHARMACEUTICAL CO. LTD. · Jul 11, 2025
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.
- Exclusion Criteria:
- • Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.
About Shin Poong Pharmaceutical Co. Ltd.
Shin Poong Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a robust pipeline spanning various therapeutic areas, including oncology, infectious diseases, and cardiovascular health, the company is committed to advancing healthcare through cutting-edge research and high-quality products. Leveraging state-of-the-art facilities and a team of experienced professionals, Shin Poong Pharmaceutical aims to address unmet medical needs and improve patient outcomes globally, while adhering to rigorous regulatory standards and ethical practices in clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported